HI-Bio was established on the premise that treatments for immune-mediated illnesses have the potential to provide patients with better outcomes. Many IMDs are caused by immune system cells, such as mast cells, neutrophils, plasma cells, and more, which are dysfunctional. These cells are in charge of crucial processes and functions. With the useof medicines, HI-efforts Bio uses a precision medicine strategy to target, modify or deplete key cellular disease drivers.HI-Bio was established in 2021 in San Francisco, California.

Biotechnology

Health Care

Life Sciences

Therapeutics

HI-Bio

Travis Murdoch, MD

Janet L.

Lorna Dean

Melisa Martin

Matthew Albert, MD, PhD

Houston Gilbert

Gijsbert Grotenbreg

David Schisla

Research & Development

Development and Clinical Operations

Leadership Team

Teams at HI-Bio

Research & Development

Development and Clinical Operations

Leadership Team